CH BIOTECH SER (08037) introduces strategic investor Mr. Gong Hongjia, opening a new chapter of industrial synergy and secondary growth.

On December 30th, the board of directors of CH BIOTECH SER (08037) officially announced that they plan to issue $35 million (approximately HK$272 million) 4-year convertible bonds to Fuchesi Holdings controlled by renowned investor Mr. Gong Hongjia. This transaction is not just a financial financing activity, but from the perspective of the capital market, the industry confidence signal and resource integration value it releases far exceed the injection of funds itself. It signifies that CH BIOTECH SER has found a strategic partner at a crucial development stage, injecting significant impetus into the upgrade of the company's core business and the layout of the entire industry chain. 1. Significant strategic investor entry: Dual endorsement of industry support and resource empowerment Mr. Gong Hongjia, as a benchmark figure in the Chinese investment and industrial sectors, has created multiple industry benchmark cases with decades of deep cultivation in the medical health and telecom technology fields. Ranked 29th on the 2022 Forbes China Rich List, he is not only known for his precise industry insights but also praised for his concept of "patient capital" empowering long-term enterprise development. One of the most well-known cases in his investment career is his angel investment and co-founding of the world's leading security company Hangzhou Hikvision Digital Technology (002415.SZ), which has become one of the most successful angel investment cases in the Chinese investment community, demonstrating his excellent ability to identify quality tracks and accompany the growth of enterprises. In the field of major health, Mr. Gong Hongjia's layout is equally profound and accurate: serving as the chairman and major shareholder of Vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH), a leading company in China's stem cell preparation, testing, and storage industry, and also controlling HeYuan Bio, which focuses on cell therapy. These two major core layouts align highly with CH BIOTECH SER's "testing business + CAR-T cell therapy + BNCT boron neutron capture therapy" strategic tricycle, especially in the areas of testing technology iteration and cell therapy industrialization. The complementary resources between the two parties are extremely strong, laying a solid foundation for deep collaboration in the future. The entry of heavyweight industrial investors at this critical juncture is essentially a deep recognition of CH BIOTECH SER's business layout, development stage, and core technological value, forming a golden combination of "critical stage + critical investor + critical business". 2. Precise alignment of core businesses: Breakthrough in BNCT technology and synergistic effects The core focus of Mr. Gong Hongjia's strategic investment this time lies in CH BIOTECH SER's forward layout and breakthrough progress in the field of BNCT boron neutron capture therapy. As a leading new technology in cancer radiation therapy globally, BNCT, with its core advantages of "precision targeting, significant efficacy, and minimal side effects," has shown remarkable curative potential in clinical applications, bringing new hope for late-stage cancer patients and becoming one of the core tracks in the global biomedicine field. The establishment and promotion of PENGBO (Hainan) Boron Neutron Hospital under CH BIOTECH SER plays a crucial role in seizing the high ground of the BNCT industry. Established in 2022 in the Boao International Medical Tourism Pilot Zone in Hainan, which is enriched with policy dividends, the hospital focuses on providing high-end BNCT medical services. It has successfully introduced the world's only advanced BNCT cancer treatment system that has been listed, and completed the beam adjustment in November 2025, with expectations to officially admit patients in the first quarter of 2026. Previously, due to financial constraints, the pace of the company's BNCT business layout had slowed down; however, with the strategic capital injection from Mr. Gong Hongjia and the empowerment of his accumulated industry resources, channel networks, and management experience in the major health field, this will effectively overcome financial constraints, accelerate the clinical promotion of BNCT technology, market penetration, and integration of the industrial chain upstream and downstream. At the same time, the mature layout in testing technology and cell therapy fields by Mr. Gong Hongjia's controlled enterprises can synergize with BNCT treatment to form a "diagnosis-treatment-recovery" full-process synergy, further amplifying the technological value and commercial potential, allowing this revolutionary treatment technology to benefit a larger number of cancer patients faster. 3. Dual drive of policy and market: BNCT industry enters the fast lane of accelerated development The conclusion of this strategic cooperation comes at a golden period when the BNCT industry is experiencing a dual explosion of policy support and market demand. From a policy perspective, the National Medical Products Administration has included BNCT-related projects in a priority approval channel, significantly shortening the policy cycle for technology implementation; more importantly, BNCT technology has been included in the "Fifteenth Five-Year Plan" for the first time, marking its elevation to a strategically supported emerging industry by the country, providing clear policy guidance and resource security for industry development. From a market perspective, with the continuous increase in cancer incidence rates and the increasingly urgent demand from patients for precision treatment, BNCT, as an innovative treatment option with curative potential, has a vast market space. Currently, domestic enterprises and medical institutions are accelerating their layout in the BNCT industry, and the industry competitive landscape is gradually taking shape, ushering in a fast lane of development. By virtue of its first-mover advantage in the Boao pilot zone, the leading global equipment configuration, and the upcoming clinical services, CH BIOTECH SER has built significant industry barriers. Mr. Gong Hongjia's strategic entry will further strengthen the company's core competitiveness in terms of capital, resources, and industry synergy, helping the company seize the initiative in the entire BNCT industrial chain layout, and consolidate its leading position in the industry. 4. Summary and Prospects: Second growth period officially begins, value reshaping is worth looking forward to The introduction of Mr. Gong Hongjia as a strategic investor by CH BIOTECH SER is a milestone event in the company's development journey. This cooperation is not just a simple supplement of funds, but a deep binding of industrial capital and quality tracks, it is a mutual empowerment of "patient capital" and technological innovation. With the arrival of strategic funds, the integration of industrial resources, and the official operation of the BNCT hospital, CH BIOTECH SER will effectively break through the development bottleneck and fully embark on the second growth period. In the future, against the backdrop of continued policy dividends and rapid market demand growth, CH BIOTECH SER will focus on BNCT technology, rely on the synergistic effects with enterprises under Mr. Gong Hongjia, deepen the strategic layout of the "three-horse chariot," accelerate the industrialization of technology, the scaling of services, and the integration of the industrial chain. We have reason to believe that this strategic cooperation will propel CH BIOTECH SER to achieve value reshaping and leapfrog development, create long-term stable returns for investors, and make significant contributions to the technological progress in cancer treatment in China and the well-being of patients. Let us look forward to it together.